# Selected Parameters Which Support the Laboratory Diagnosis of Cardiovascular-Kidney-Metabolic Syndrome in the Light of Current Guidelines: A Narrative Review

**Authors:** Michał Sławiński, Justyna Bugajska, Katarzyna Dąbrowska, Jacek Różański, Andrzej Brodkiewicz, Jeremy S. C. Clark, Violetta Sulżyc-Bielicka, Robert Nowak, Dorota Kostrzewa-Nowak

PMC · DOI: 10.3390/jcm15041456 · 2026-02-12

## TL;DR

This paper reviews how combining cardiovascular, kidney, and metabolic disease concepts improves diagnosis and treatment through early lab assessments.

## Contribution

It highlights updated laboratory parameters for diagnosing cardiovascular-kidney-metabolic syndrome based on recent guidelines.

## Key findings

- Early laboratory assessment improves risk stratification and patient classification.
- Shared molecular mechanisms enhance diagnostic accuracy and preventive strategies.
- Selected lab parameters align current knowledge with emerging clinical recommendations.

## Abstract

Progression in understanding the relationships among cardiovascular, kidney, and metabolic diseases necessitates reappraising these concepts. Here, this narrative review explains the evolution of the ideas behind cardiovascular-kidney-metabolic syndrome (CKMS), focusing both on the impact of kidney disease on the cardiovascular system and metabolic syndrome and, conversely, on the effects of metabolic syndrome on cardiovascular and kidney diseases. Merging these concepts has resulted in a holistic approach more pertinent to managing the increased pressure from civilization diseases. In light of recent guidelines, early laboratory assessment is critical for risk stratification by improved patient classification, enabling individualized therapeutic strategies. Moreover, understanding the molecular mechanisms common to these systemic disorders not only enhances diagnostic accuracy but also facilitates the implementation of preventive measures that target multiple organ pathologies simultaneously. This review summarizes selected laboratory parameters that may support the diagnosis and management of cardiovascular-kidney-metabolic syndrome, aligning current knowledge with emerging clinical recommendations.

## Linked entities

- **Diseases:** cardiovascular-kidney-metabolic syndrome (MONDO:0976301), metabolic syndrome (MONDO:0000816)

## Full-text entities

- **Genes:** REN (renin) [NCBI Gene 5972] {aka ADTKD4, HNFJ2, RTD}, NOS3 (nitric oxide synthase 3) [NCBI Gene 4846] {aka EC-NOS, ECNOS, MYMY8, NOSIII, cNOS, eNOS}, RENBP (renin binding protein) [NCBI Gene 5973] {aka RBP, RNBP}, PRRT2 (proline rich transmembrane protein 2) [NCBI Gene 112476] {aka BFIC2, BFIS2, DSPB3, DYT10, EKD1, FICCA}, CST3 (cystatin C) [NCBI Gene 1471] {aka ADLDWA, ARMD11, HEL-S-2}, AGER (advanced glycosylation end-product specific receptor) [NCBI Gene 177] {aka RAGE, SCARJ1, sRAGE}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, NPPB (natriuretic peptide B) [NCBI Gene 4879] {aka BNP, Iso-ANP}
- **Diseases:** glycemic disorders (MESH:D009358), hypertensive nephropathy (MESH:C563161), sepsis (MESH:D018805), hypertriglyceridemia (MESH:D015228), Metabolic disorders (MESH:D008659), Hyperuricemia (MESH:D033461), impairment of myocardial and renal perfusion (MESH:D006030), impaired glucose tolerance (MESH:D018149), visceral obesity (MESH:D056128), diabetic kidney disease (MESH:D003928), pulmonary embolism (MESH:D011655), lipid abnormalities (MESH:D011017), reduced muscle mass (MESH:D009135), noncommunicable (MESH:D000073296), cardiac, and renal disorders (MESH:D006331), coronary artery calcification (MESH:D003324), deterioration of renal function (MESH:D058186), myocarditis (MESH:D009205), overweight (MESH:D050177), stroke (MESH:D020521), weight gain (MESH:D015430), estrogen (MESH:D056828), structural abnormalities (MESH:C566527), type 2 diabetes (MESH:D003924), Obesity (MESH:D009765), HDLC (MESH:D052456), adiposity (MESH:D018205), calcium disorders (MESH:D002128), CKM (MESH:D007674), arrhythmias (MESH:D001145), multi-organ dysfunction (MESH:D009102), primary hypertension (MESH:D000075222), HF (MESH:D006333), infarction (MESH:D007238), organ damage (MESH:D000092124), androgen axis disorders (MESH:D014770), liver fibrosis (MESH:D008103), familial hypercholesterolemia (MESH:D006938), prediabetes (MESH:D011236), Hormonal disorders (MESH:C565870), vascular damage (MESH:D057772), health disorder (OMIM:603663), impaired glucose metabolism (MESH:D044882), Insulin Resistance (MESH:D007333), heart defects (MESH:D006330), CKD (MESH:D051436), Hypoglycemia (MESH:D007003), CVD (MESH:D002318), dyspnea (MESH:D004417), nonalcoholic fatty liver disease (MESH:D065626), heart attack (MESH:D009203), kidney failure (MESH:D051437), endocrine dysregulation (MESH:D004700), cancer (MESH:D009369), diminished cardiac output (MESH:D002303), Diabetes (MESH:D003920), atrial fibrillation (MESH:D001281), endothelial dysfunction (MESH:D014652), lung disease (MESH:D008171), ischemic heart disease (MESH:D017202)
- **Chemicals:** ketone bodies (MESH:D007657), Cholesterol (MESH:D002784), nitric oxide (MESH:D009569), Glucose (MESH:D005947), creatinine (MESH:D003404), ROS (MESH:D017382), hexosamine (MESH:D006595), lipid (MESH:D008055), testosterone (MESH:D013739), purine (MESH:C030985), NaF (MESH:D012969), AGEs (MESH:D017127), aldosterone (MESH:D000450), Triglycerides (MESH:D014280), bilirubin (MESH:D001663), polyol (MESH:C024617), Uric acid (MESH:D014527), prostaglandins (MESH:D011453), sodium (MESH:D012964), CysC (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12941782/full.md

---
Source: https://tomesphere.com/paper/PMC12941782